Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis - Wikidata - wikimedia - TriplyDB

Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis

Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis

http://www.wikidata.org/entity/Q58211896

about

The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.VEGF targets the tumour cell.Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.Pathway enrichment analysis approach based on topological structure and updated annotation of pathway.Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations.

P2860

Q33444299-2F0F13F8-81B0-4C37-8875-272C8AE4D21B Q33475963-A4B7092D-5881-487E-91D8-C6365E1431DD Q33573324-DD8B0E4C-9440-48D8-B599-E2778C04AB0A Q33682981-2D8B0040-4080-4D8A-A293-3B53ED9248F0 Q34040956-3D55ECF7-E96E-454F-9C5E-26AAC013470F Q35180428-16352299-EAA6-48AD-B0AB-5E02F439BBBD Q36191443-D5061BC1-3406-444A-8948-55AB74CD572D Q36691776-6A1DB7BC-457A-4BE9-8497-3F73E272F9A7 Q36977529-F8DAFC2D-FA08-4028-9524-C518433D3801 Q39747275-2EBE9889-5D1F-4622-B411-DBD95256984B Q40761584-E33E0E17-6369-4C91-A609-F637CF149887 Q47884625-7628EAAD-9A27-4D93-8570-D4CABB3545F5 Q55448998-603CC13F-56FC-4A7D-BB90-F157B84277FC

P2860

Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis

http://www.wikidata.org/entity/Q58211896

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2006

@uk

name

Phosphorylated KDR expression ...... way and unfavourable prognosis

@en

Phosphorylated KDR expression ...... way and unfavourable prognosis

@nl

type

label

Phosphorylated KDR expression ...... way and unfavourable prognosis

@en

Phosphorylated KDR expression ...... way and unfavourable prognosis

@nl

prefLabel

Phosphorylated KDR expression ...... way and unfavourable prognosis

@en

Phosphorylated KDR expression ...... way and unfavourable prognosis

@nl

P1433

Q58211896-A05EB773-FBCE-4389-B99D-FAFAD800E2C0

P1476

Q58211896-9949FB27-3853-4C25-9EFD-3F6DFDF0B325

P2093

Q58211896-5E1CD11B-A46F-440F-A180-F8ABEA0D1732

Q58211896-62FAC6E4-6FC2-4BF1-AFA6-65D98D67A87A

Q58211896-89D5D278-9CFF-4B2D-89E8-12DAF05AAB9F

Q58211896-B3DD5E14-B32F-4586-8B27-8EC27C7E0FAE

Q58211896-F11E9AFB-10C8-4561-BFED-137CFD0EA019

P2860

Q58211896-0F2A435E-413A-47E1-858F-93FB490869CF

Q58211896-1938FB7C-9535-4402-A48D-792A6A513711

Q58211896-2308772A-CFAF-490A-850B-49FC6FEACE98

Q58211896-32D39DC1-1F4B-421C-BAE6-F094D1D5651F

Q58211896-34EAF849-7CE5-4C0F-9179-6C7C7890A5DF

Q58211896-3FF1B8ED-058D-46F3-8E13-DE37C3DDF4E2

Q58211896-63AEBBDC-92D1-47C4-9162-45665E105737

Q58211896-64736470-B6DF-4992-B1B8-91EB820D46AF

Q58211896-6519C3AA-27DF-4907-8510-7E95079C8888

Q58211896-684AC306-C85D-40A2-BC28-2EE32E197EC3

P2888

Q58211896-AB723925-6D5E-47F9-B815-F66C16128FC4

P304

Q58211896-6410E0A7-F2CE-42A7-AD8A-E06D05114977

P31

Q58211896-E3BB3FCA-3C66-42D9-8B09-9D389B31D87E

P356

Q58211896-1B2E7A86-C703-4F59-8034-DD73D946FF25

P433

Q58211896-9A286A8B-259C-4797-8886-EEACFF69C744

P478

Q58211896-6D8BC239-AA3F-4130-8C2D-5C3CE0796107

P50

Q58211896-2654177E-A1B0-4035-A909-0CE402F01F12

P577

Q58211896-AE998734-7033-4433-8C3E-0CD68F144F7A

P698

Q58211896-364A1217-145A-4389-8E0F-DC06B8F3604B

P921

Q58211896-5089D07C-8F43-4357-B660-7E67CE0834DF

P356

MODPATHOL.3800579

P1433

Modern Pathology

P1476

Phosphorylated KDR expression ...... way and unfavourable prognosis

@en

P2093

Alexandra Giatromanolaki

http://www.w3.org/2001/XMLSchema#string

Efthimios Sivridis

http://www.w3.org/2001/XMLSchema#string

Helen Turley

http://www.w3.org/2001/XMLSchema#string

Kevin C Gatter

http://www.w3.org/2001/XMLSchema#string

Michael I Koukourakis

http://www.w3.org/2001/XMLSchema#string

P2860

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts

Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.

Prognostic aspects on endometrial hyperplasia and neoplasia.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration

Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.

Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants.

Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.

P2888

modpathol.3800579

P304

701-707

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.3800579

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

P577

2006-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16557278

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation